Strontium malonate is a dual acting bone agent which stimulates bone formation & reduces bone resorption . There have been a number of research studies. Here are recent results:
1. Researchers in Denmark have studies it. They are developing itas a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. As part of this development the compound was administered in doses of 0 (placebo), 300, 1000 and 3000 mg/kg/day to beagle dogs for a period of 4 weeks.
They measured the incorporation of strontium in bone, marrow and teeth in their study. . . .. Bone samples showed an approximately 80 fold increase in strontium content in the dogs treated with 300 mg/kg/day compared to placebo. The higher dose groups showed only marginally higher incorporation of strontium suggesting that saturation levels were reached with the lowest dose level.
2. Osteologix did a Phase II study of Strontium malonate
The NB S101 stated in the study is a once-daily tablet formulation that was primarily evaluated for its effect on bone resorption. A total of 289 postmenopausal women, age >50, with low BMD were randomized to 5 groups and treated for 12 wks.
1: Baseline demographics of the study cohort. No parameter differed significantly between the groups at baseline.
2. RESULTS: . . The mean percent change over 12 wks as compared to placebo. NB S101 significantly reduced CTX-1 in all dose groups and achieved greater reductions in CTX-1 than Protelos, with the 2g NB S101 dose achieving significantly greater reductions (p<0.01) in CTX-1 than Protelos. NOTE: ctx-1 is a bone marker.
3. Adverse events included diarrhea, nausea, fatigue, back pain, headache, and muscle spasms. Potentially-related serious AEs with NB S101 included one event each of deep vein thrombosis, TIA, and allergic reaction. The frequency and types of AEs reported for patients with NB S101 at all three doses were comparable to those after treatment with the active comparator, Protelos.
Another study was reported at the European Calcified Tissue Society meeting. It concluded that:
"All 3 doses of NB S101 were well-tolerated and significantly suppressed bone resorption while improving BMD. The resultsconsistently show that NB S101 wassafe and well tolerated and waseffective on bone turnover and BMD in the short-term; it merits development as a treatment for postmenopausal osteoporosis"
Authors: K. Brixen, K. Krogsgaard, S. Christgau, , M. Weis ,, R. Eastell, Dept of Endocrinology, Odense University Hospital, Odense, ; PhaseOneTrials, Hvidovre Hospital, Hvidovre, Research and development, Clinical Development, Osteologix, Copenhagen, Denmark, Metabolic Bone Centre, SheffieldUniversity, Sheffield, United Kingdom
That is it as of October 2014. If you come across another, more recent study, I would appreciate your using the form below to let me know of the study and its ABSTRACT. Thank you in advance.